After Ruikang Medical's Danish branch submitted relevant information on cancer cell gene-edited drugs and some clinical data in China to the Ministry of Health, the Danish health department immediately approved the application to conduct clinical trials in its own country!

For Denmark, this new drug from Ruikang Medical is simply a savior!

Although their cancer incidence cannot be reduced, it can improve the survival rate of cancer patients, which can reduce the mortality rate of cancer patients every year!

The proportion of cancer patients in their country is not low at all!

To put it bluntly, if these patients who could only lie in bed and wait for death could be liberated, they could temporarily recover their health and return to society to work, even if it was only ten or twenty years, it would have added a lot of available labor to Denmark...

So after they urgently consulted internally, the Danish Ministry of Health chose the latter between the potential dangers of gene editing technology and the salvage of increasingly severe cancer incidence in their country.

The cancer cell gene editing drug was successfully carried out clinical trials in Denmark. The five-person team sent from the Nandou Scientific Research Center to Denmark, as well as the subsequent gene editing drug, quickly invested in clinical practice in several large hospitals in the Danish capital and began to conduct trials on the Danes.

However, no matter how fast it is, it will take two or three months to get a preliminary result. Chen Changan can only wait for good news in China for the time being.

However, less than two days later, Director Kang was a little sad because of the pace of the cancer cell gene editing drug being launched in China. Another project of Ruikang, Chen Changan, originally gave it to the production center to ask them to try to produce the artificial heart valve, passed the market approval smoothly.

This interventional artificial valve combines the advantages of biological valves and mechanical valves, and is also the first interventional mitral valve and tricuspid valve in China.

Once launched, under the influence of Ruikang Medical's brand, 142 hospitals in China that can carry out TAVR surgery have been quickly opened up.

In the past, patients who had interventional valve replacement surgery could only replace the aortic valve. Patients with mitral and tricuspid valve damage like Guan Kou's father could only choose traditional thoracic surgery. Not only did the risk be high, the prognosis effect was not good.

Ruikang Medical's new product has expanded the scope of TAVR surgery from only aortic valve replacement to the ability to replace all heart valves, providing more advanced treatment options for patients with heart valve injuries.

The only pity is that there are currently few hospitals in China that can perform TAVR surgery, with only 142. Even if these hospitals are willing to purchase Ruikang's interventional valves, the order volume is not large, and the profit is only 18 million yuan a year.

This profit may be very good for Chen Changan when he first took over the company, which was enough for him to be happy for a while, but for Chen Changan, whose Ruikang products are now hot all over the world, it is just a icing on the cake.

However, this has enriched Ruikang's product line. After all, Ruikang's time to start is still too short, and there are only a few products under it. Although the annual output value is tens of billions, most of them are contributed by artificial hematopoietic equipment and cardiomyocyte therapy agents.

If Ruikang wants to become a large group with a strong influence in the medical industry, it still needs more products to lay the foundation.

The launch of interventional valves is a very good start!

However, when he tried to promote this new product to the medical market in other countries, he encountered setbacks. Medtronic and Boston Science's similar products had long occupied the share of most countries in the world, and there was no room for Ruikon to intervene.

Ruikang tried to promote it in branches in various countries, but the results were not very good. Even in countries such as Britain, the United States, Germany, Ruikang's interventional valve did not obtain a marketing authorization...

This also made Chen Changan helpless and made him see a truth clearly, although Ruikang seemed to have achieved some achievements in countries around the world.

However, in the field of traditional medical equipment, it is still unrealistic for Ruikang to get a share of the pie with these medical giants. As long as they have similar products on sale, it will be difficult for Ruikang to grab the market from them.

The ability of Kirin ventilator to regain the market occupied by European and American medical giants in China was just a blitzkrieg that caught off guard. After going overseas, it has made no achievements except to grab some markets in Southeast Asia and other countries through price wars.

In the existing medical equipment field, it is still difficult for Ruikang to compete with giants such as Medtronic and Siemens to compete for the market.

This also poured a pot of cold water on Chen Changan, who has been immersed in Ruikang's artificial hematopoietic equipment and cardiomyocyte therapy drugs for more than a year and has sold his heart to the point of being invincible!

Successfully pulled him back from this inflated mentality, making him realize that Ruikang still has a big gap with these medical groups that have been rooted in countries around the world for decades, and it is still too early to laugh.

Ruikang is now just relying on his skills to gain a foothold in the world's medical industry. It is still too early to truly grasp the voice of the medical industry and influence the development of the industry!

Thinking of this, Chen Changan, after arranging Guan Kou to personally monitor the subsequent progress of the Danish branch, plunged into the Nandou Research Center again.

After all, Chen Changan has not participated in the company's R&D project for a long time since the artificial hematopoietic equipment project was completed.

On the one hand, it was because Yun Heng’s gene editing project and Wang Jia’s cardiomyocyte healing project were both pure biomedical projects. He didn’t understand these very well and could not provide much help.

After all, he has mastered some relevant knowledge of medical equipment, and he really doesn't master much of histocytology, genes and other aspects.

It’s okay to let him participate in the research and development of some medical devices and equipment, but he basically can’t help with the development of this genetic drug, so he can only provide some ideas or some related papers.

The two projects of cancer cell gene editing drugs and cardiomyocyte therapy drugs were basically completed independently by Yun Heng and Wang Jia. Chen Changan only provided a solution to extend the cell survival cycle.

This also indirectly shows that Yun Heng and Wang Jia's scientific research capabilities are indeed excellent, and they are definitely a master of genes and histology!

However, the visual prosthesis device project that Wang Jia is currently carrying out is a serious medical equipment research and development, and the research and development of Wang Jia's project team is still very unsuccessful. After all, this is a visual perception device that has never been tried before, and there are many technical difficulties that need to be overcome!
Chapter completed!